Conv. Plasma
Nigella Sativa

All HCQ studies
Meta analysis
study COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 18% Improvement Relative Risk HCQ for COVID-19  Ubaldo et al.  ICU PATIENTS Is very late treatment with HCQ beneficial for COVID-19? Retrospective 31 patients in Philippines No significant difference in mortality Ubaldo et al., Critical Care Research .., Feb 2021 Favors HCQ Favors control

COVID-19: A Single-Center ICU Experience of the First Wave in the Philippines

Ubaldo et al., Critical Care Research and Practice, 10.1155/2021/7510306
Feb 2021  
  Source   PDF   All   Meta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
*, now known with p < 0.00000000001 from 422 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments.
Retrospective ICU patients in the Philippines showing unadjusted HCQ RR 0.82, p = 0.64.
Although the 18% lower mortality is not statistically significant, it is consistent with the significant 25% lower mortality [20‑29%] from meta analysis of the 250 mortality results to date.
This study is excluded in the after exclusion results of meta analysis: substantial unadjusted confounding by indication likely; very late stage, ICU patients; unadjusted results with no group details.
risk of death, 18.4% lower, RR 0.82, p = 0.64, treatment 17 of 25 (68.0%), control 5 of 6 (83.3%), NNT 6.5, COVID-19 positive patients.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Ubaldo et al., 1 Feb 2021, retrospective, Philippines, peer-reviewed, 3 authors.
This PaperHCQAll
COVID-19: A Single-Center ICU Experience of the First Wave in the Philippines
Onion Gerald V Ubaldo, Jose Emmanuel M Palo, Jude Erric L Cinco
Critical Care Research and Practice, doi:10.1155/2021/7510306
On January 30, 2020, the WHO declared the novel coronavirus of 2019 a pandemic, causing millions of cases and thousands of deaths worldwide, exposing the vulnerabilities of healthcare systems around the world with each country having its own experience. ese ranged from patient clinical profiles to management recommendations and to government interventions. ere is a paucity of published data regarding Philippine experience. is study is a retrospective, descriptive study of ninety-one COVID-19 probable patients admitted in the COVID ICU of e Medical City from March 16 to May 7, 2020. We described clinical and demographic characteristics amongst COVID-19-confirmed and -negative patients. erapeutic interventions including COVID-19 investigational drug use and other organ failure strategies were noted and tested for association with ICU survivors and nonsurvivors. We observed that there was no therapeutic intervention that was associated with improved outcomes, with some interventions showing trends favoring the ICU nonsurvivor group. ese interventions include, but are not limited to, the use of hydroxychloroquine and tocilizumab, and prone positioning. We also observed that a higher SAPS-3 score was associated with the COVID-19 positive group and the ICU nonsurvivor group. On PubMed search, there seems to be no Philippine-specific literature regarding COVID-19 ICU experience. Further investigations to include more variables are recommended.
Conflicts of Interest e authors declare no conflicts of interest.
Benítez, Güemes, Cunha De Resende Brasil, Impact of personal protective equipment on surgical performance during the COVID-19 pandemic, World Journal of Surgery
Bhatraju, Ghassemieh, Nichols, Covid-19 in critically ill patients in the seattle region-case series, e New England Journal of Medicine
Bos, Schultz, Schultz, ARDS: challenges in patient care and frontiers in research, European Respiratory Review
Cao, Wang, Wen, A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19, Proceedings of the National Academy of Sciences
Caputo, Strayer, Levitan, Early self-proning in awake, non-intubated patients in the emergency department: a single ED's experience during the COVID 19 pandemic, Academic Emergency Medicine
Di Saverio, Khan, Pata, Laparoscopy at all costs? Not now during COVID-19 outbreak and not for acute care surgery and emergency colorectal surgery: a practical algorithm from a hub tertiary teaching hospital in Northern Lombardy, Italy, Journal of Trauma and Acute Care Surgery
Du, Tu, Zhu, Clinical features of 85 fatal cases of COVID-19 from Wuhan: a retrospective observational study, SSRN Electronic Journal
Edrada, Lopez, Villarama, First COVID-19 infections in the Philippines: a case report, Tropical Medicine and Health
Flisiak, Horban, Jaroszewicz, Recommendations of management in SARS-CoV-2 infection of the polish association of epidemiologists and infectiologists, Polish Archives of Internal Medicine
Gattinoni, Chiumello, Caironi, COVID-19 pneumonia: different respiratory treatments for different phenotypes?, Intensive Care Medicine
Gattinoni, Chiumello, Rossi, COVID-19 pneumonia: ARDS or not?, Critical Care
Joseph, Moslehi, Hogarth, Majid, Meng, International pulmonologist's consensus on COVID-19
Leung, Wu, Liu, Leung, First-wave COVID-19 transmissibility and severity in China outside Hubei after control measures, and second-wave scenario planning: a modelling impact assessment, e Lancet
Li, Yu, Du, Covid-19 in China: ten critical issues for intensive care medicine, Critical Care
Lima, Ribeiro Junior, Vieira, Campos, Saverio, Early self-proning in awake, non-intubated patients in the emergency department: a single ED's experience during the COVID-19 pandemic, Academic Emergency Medicine
Liu, Li, Feng, Critical care response to a hospital outbreak of the 2019-nCoV infection in Shenzhen, China, Critical Care
Mehra, Ruschitzka, Patel, Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis, Lancet
Phual, Mrcp, Review Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations, e Lancet Respiratory
Sohrabi, Alsafi, O'neill, World Health Organization declares global emergency: a review of the 2019 novel coronavirus (COVID-19), International Journal of Surgery
Steffens, A hundred days into the coronavirus disease (COVID-19) pandemic, Eurosurveillance
Sztajnbok, Maselli-Schoueri, De Resende Brasil, Prone positioning to improve oxygenation and relieve respiratory symptoms in awake, spontaneously breathing non-intubated patients with COVID-19 pneumonia, Respiratory Medicine Case Reports
Vardanjani, Moayedi, COVID-19 pandemic hemoperfusion therapy versus plasma exchange therapy in intensive care, Iran Journal of Allergy Ashtma Immunology
Xu, Han, Li, Effective treatment of severe COVID-19 patients with tocilizumab, Post-Publication Peer Review of the Biomedical Literature
Zhou, Yu, Du, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, e Lancet
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop